A Retrospective Study to Evaluate NeuroStar® Advanced Therapy in Adolescents

NCT06699940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7690

Last updated 2025-01-06

No results posted yet for this study

Summary

To assess the real-world effectiveness of transcranial magnetic stimulation (TMS) for depression in large adolescent and young adult samples.

Conditions

Interventions

DEVICE

Transcranial Magnetic Stimulation

Patients between the age of 12-21 received TMS treatment for MDD disorder.

Sponsors & Collaborators

  • Neuronetics

    lead OTHER

Principal Investigators

  • Eleanor Cole, PhD · Neuronetics

Eligibility

Min Age
12 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2023-05-01
Completion
2023-05-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06699940 on ClinicalTrials.gov